AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22859618
Drug: De‐alcoholized red
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De‐alcoholized red wine (450 ml daily for 4 weeks)
Trial: 19191781
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel treatment
Trial: 19191781
Drug: Every 3
RxNorm normalized name: Eligard Every 3 Months 22.5 MG per 0.375 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 3 weeks paclitaxel treatment
Trial: 10857142
Drug: Terazosin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (5 mg per day in single dose)
Trial: 10857142
Drug: Alfuzosin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (7.5 mg per day in 3 doses)
Trial: 9358213
Drug: 5-FU monotherapy
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU monotherapy (600 mg/m2)
Trial: 9358213
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5-FU (600 or 400 mg/m2) and high-dose FA (400 mg/m2)
Trial: 8257226
Drug: Neostigmine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.5 mg)
Trial: 25403253
Drug: Subacromial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial injection therapy (Betamethasone plus prilocaine)
Trial: 25202858
Drug: Prophylactic administration
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic administration of fresh frozen plasma (FFP)
Trial: 19384779
Drug: IOL optic
RxNorm normalized name: Opti-Nail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOL optic captured behind the posterior capsule with posterior capsulotomy (group 1)
Trial: 12148300
Drug: Bupivacain 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacain 0.5% (4 ml) injected retrobulbarly before surgery (group I)
Trial: 12148300
Drug: Bupivacain 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacain 0.5% (4 ml) injected retrobulbarly after surgery (group II)
Trial: 9586589
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy with selective, long‐acting, alpha1‐blocking agents (terazosin, doxazosin, tamsulosin)
Trial: 9586589
Drug: Finasteride (5‐alpha‐reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5‐alpha‐reductase inhibitor)
Trial: 9586589
Drug: Device therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device therapies (Laser prostatectomy including VLAP, TUEP, TILP)
Trial: 9586589
Drug: Medical and
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical and device therapies
Trial: 7862899
Drug: Ethanol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.8 ml/kg body weight)
Trial: 7862899
Drug: Alcohol treatments
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatments
Trial: 2536911
Drug: MAC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAC chemotherapy (methotrexate, dactinomycin, and chlorambucil)
Trial: 17947605
Drug: Enteral formula
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral formula containing 50 g of saccharides enriched with 2.3 g of fiber/100 mL
Trial: 17947605
Drug: Enteral formula
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral formula containing 50 g of saccharides
Trial: 9621141
Drug: Recombinant IFN-beta
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant IFN-beta (0.15 x 10(6) IU/g) applied 5 times daily for 4 weeks
Trial: 9621141
Drug: Recombinant IFN-beta
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant IFN-beta (1.0 x 10(6) IU/g) applied 5 times daily for 4 weeks
Trial: 9621141
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied 5 times daily for 4 weeks
Trial: 7633951
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon-alpha cream (2 x 10(6) IU/g) applied three times daily for 5 consecutive days
Trial: 7633951
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied three times daily for 5 consecutive days
Trial: 7633951
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon-alpha cream
Trial: 330080
Drug: Sulindac given
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac given twice daily (100 to 300 mg daily, adjusted according to patient response)
Trial: 330080
Drug: Sulindac given
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac given 4 times daily (100 to 300 mg daily, adjusted according to patient response)
Trial: 26321524
Drug: Yupingfeng granules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yupingfeng granules, 10 g/time, tid for 2 courses
Trial: 26321524
Drug: Synchronous radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synchronous radiotherapy and chemotherapy (Control)
Trial: 21519814
Drug: 4-week schedule
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week schedule of gemcitabine (1000 mg/m² as a 30-min infusion weekly for 3 consecutive weeks every 4 weeks)
Trial: 21519814
Drug: 3-week schedule
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week schedule of gemcitabine (1000 mg/m² as a 30-min infusion weekly for 2 consecutive weeks every 3 weeks)
Trial: 16549639
Drug: Total homocysteine
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total homocysteine (tHcy) measured in tertiles (<14.7, 14.7 to 19.5, > or =19.6 micromol/L)
Trial: 12131319
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin substitution
Trial: 9817273
Drug: 500 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/m2 amifostine intravenously before HD-RIT
Trial: 17390690
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline solution (Control)
Trial: 28079825
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg administered at loss of eyelash reflex (Control group C; n=45)
Trial: 28079825
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg administered when BIS fell to less than 40 (Experimental group T; n=45)
Trial: 28079825
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg administered when BIS fell below 40 after manual ventilation with sevoflurane (Experimental group S; n=45)
Trial: 11685593
Drug: 7 days'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days' intravenous antibiotics (group A)
Trial: 11685593
Drug: 3 days'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days' intravenous antibiotics (group B)
Trial: 8186347
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg/day for 3 days
Trial: 8186347
Drug: No-drug control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-drug control period
Trial: 3369330
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections with strict surveillance of alcohol intake
Trial: 3369330
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections without surveillance
Trial: 3369330
Drug: No placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No placebo injections with surveillance
Trial: 3369330
Drug: No placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No placebo injections without surveillance
Trial: 30550515
Drug: BLmax ≥8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLmax ≥8 mmol·L
Trial: 26348533
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of olodaterol (0.5-25 μg)
Trial: 26348533
Drug: Oral inhalation
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation of olodaterol (2.5-70 μg via Respimat® inhaler)
Trial: 17981449
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (1.84 g/day of EPA and DHA)
Trial: 16439505
Drug: Auto-crosslinked hyaluronan
RxNorm normalized name: hyaluronic acid, crosslinked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auto-crosslinked hyaluronan gel
Trial: 25547983
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet rich plasma (PRP) treatment
Trial: 18416281
Drug: Levetiracetam (250,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (250, 500, or 1000 mg, single dose) after acetylsalicylic acid (aspirin)
Trial: 18416281
Drug: Levetiracetam (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (twice daily for 4 days) with aspirin administered with the penultimate dose
Trial: 18416281
Drug: Levetiracetam (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (twice daily for 4.5 days)
Trial: 18416281
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 4.5 days)
Trial: 8872417
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day of tacrine
Trial: 8872417
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day of tacrine
Trial: 8872417
Drug: tacrine (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tacrine (dosage not specified) with lecithin
Trial: 1804294
Drug: Psoralen plus
RxNorm normalized name: Psoralen
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psoralen plus ultraviolet A (PUVA) therapy, oral psoralen (8‐methoxypsoralen; 0.6 mg/kg) taken at each session, 10-20 sessions 3 times per week
Trial: 1804294
Drug: Psoralen plus
RxNorm normalized name: Psoralen
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psoralen plus ultraviolet A (PUVA) therapy
Trial: 6318350
Drug: Bi‐Profenid 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi‐Profenid 150 mg
Trial: 31980156
Drug: Peri-hamstring local
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-hamstring local anaesthetic injection (Group H)
Trial: 30935601
Drug: Interactive power
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interactive power toothbrush (Oral-B Professional Care 6000, D36/EB20) with Bluetooth technology
Trial: 30935601
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral-B Indicator 35 soft)
Trial: 22867036
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill plus behavioral support
Trial: 20168306
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (240 mg/day)
Trial: 10574423
Drug: ramipril-felodipine ER
RxNorm normalized name: felodipine / ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril-felodipine ER (10/10 mg)
Trial: 10574423
Drug: ramipril-felodipine ER
RxNorm normalized name: felodipine / ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril-felodipine ER (5/5 mg)
Trial: 10574423
Drug: felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felodipine ER monotherapy
Trial: 25304277
Drug: Subconjunctival preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival preparation of 6×6 mm (group A)
Trial: 25304277
Drug: Subconjunctival preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival preparation of 8×9 mm (group B)
Trial: 21684018
Drug: Web-camera delivered
RxNorm normalized name: Calmera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-camera delivered cognitive-behavioral therapy (W-CBT)
Trial: 18008156
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant FSH commenced in the luteal phase with a long GnRH agonist protocol
Trial: 18008156
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received FSH on day 2 in a short protocol GnRH agonist regimen
Trial: 11278211
Drug: Ganirelix (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganirelix (0.25 mg, s.c.)
Trial: 11278211
Drug: Triptorelin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (0.1 mg, s.c.)
Trial: 3075434
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg orally twice a day)
Trial: 3075434
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) (160/800 mg orally twice a day)
Trial: 19104202
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy for metastatic breast cancer
Trial: 28697910
Drug: Duphaston (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duphaston (20 mg/d)
Trial: 28697910
Drug: Utrogestan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utrogestan (100 mg/d)
Trial: 25577227
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (health education and tilt training) plus ORS (with 500 ml of water) - Group I (87 patients)
Trial: 25577227
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy - Group II (79 patients)
Trial: 18931845
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K Antagonist (VKA) for 30 months
Trial: 18931845
Drug: Discontinue Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue Vitamin K Antagonist (VKA) after 6 months
Trial: 16732017
Drug: Ramipril (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (1.25 mg o.d.)
Trial: 15353428
Drug: Faxed physician
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faxed physician reminders containing osteoporosis treatment guidelines and patient education
Trial: 10755330
Drug: Extended-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin 5 to 30mg once daily
Trial: 10755330
Drug: Extended-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin 15mg once daily
Trial: 8173166
Drug: Immediate platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate platinum-based therapy
Trial: 8173166
Drug: Platinum in
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum in combination
Trial: 3669080
Drug: Marital therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marital therapy combined with symptom-specific therapy for sexual dysfunction
Trial: 3669080
Drug: Relaxation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation and information before sex therapy
Trial: 31003664
Drug: Yoga nidra
RxNorm normalized name: Mycogone nigra
DrugBank: Mycogone nigra (DB10971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga nidra (1-hour sessions, bi-weekly for 8 weeks)
Trial: 28870177
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Tripterygium wilfordii Hook F gel
Trial: 19920114
Drug: Dasatinib 70
RxNorm normalized name: dasatinib 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 70 mg twice daily
Trial: 15363067
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IGF‐I (0.05 mg/kg twice daily by subcutaneous injection)
Trial: 9700998
Drug: Cilnidipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine (5 or 10 mg once daily)
Trial: 9673431
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard (10 or 20 mg twice daily)
Trial: 8090335
Drug: Diltiazem 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 0.3 mg/kg bolus preoperatively, followed by infusion of diltiazem 3 mg/kg/24 h preoperatively and oral diltiazem for 3 months
Trial: 8090335
Drug: Placebo 0.3
RxNorm normalized name: Norethindrone;Placebo 0.35 MG; NA Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.3 mg/kg bolus preoperatively, followed by infusion of placebo 3 mg/kg/24 h preoperatively and oral placebo for 3 months
Trial: 26506778
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba injection combined with traditional therapy
Trial: 26506778
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy (control group)
Trial: 21263198
Drug: Thyroid suppression
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid suppression therapy with thyroxine (T4) 2.5µg/kg/day for two months
Trial: 19055284
Drug: Chinese drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drug (Wuzi Yanzong Pill)
Trial: 16224108
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management with oxygen therapy (control group, n = 83)
Trial: 12952258
Drug: AKITA system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKITA system (inhalation device)
Trial: 12952258
Drug: PARI‐LC Star
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARI‐LC Star (inhalation device)
Trial: 12952258
Drug: HaloLite (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HaloLite (inhalation device)
Trial: 12952258
Drug: Prolastin (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin (5% solution)
Trial: 8458457
Drug: Follicular stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follicular stimulation with CC in insemination cycles
Trial: 8458457
Drug: Follicular stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follicular stimulation with CC in intercourse cycles
Trial: 3702643
Drug: Multiple vitamin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple vitamin, multiple mineral supplement containing 18 mg iron for 8 months
Trial: 24260145
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) for social anxiety disorder
Trial: 20237361
Drug: High-dose extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose extracorporeal shockwave therapy
Trial: 19009658
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g n‐3 polyunsaturated fatty acids (PUFA) from seal oils, three times a day, along with a recommended diet
Trial: 19009658
Drug: Placebo, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 g, three times a day, along with a recommended diet
Trial: 24322182
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate 2 g daily
Trial: 18302747
Drug: Letrozole treatment
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole treatment
Trial: 25796103
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (n = 14) received 1.7 g protein/kg/day during admission and a daily protein supplement (18.8 g protein) and resistance training 3 times per week for 12 weeks after discharge